Kidney-Related Outcome in Cardiorenal Syndrome Type 3

Table 1

Baseline characteristics of all patients included.

Variable	Baseline characteristics
Gender (females/males)	42 (44.2%)/53 (55.8%)
Age (mean years+/−SD)	79.6+/−10.5
In-hospital stay (mean days+/−SD)	21.1+/−17.3
AKIN stage (1/2/3)	19 (20%)/38 (40%)/38 (40%)
Initial serum creatinine (micro-Mol/L+/−SD)	231+/−163
Peak serum creatinine (micro-Mol/L+/−SD)	347.4+/−157.2
Serum creatinine before discharge (micro-Mol/L+/−SD)	218.8+/−141.4
Initial serum sodium (mMol/L+/−SD)	137.6+/−6.2
Minimal serum sodium (mMol/L+/−SD)	135.1+/−6
Peak serum sodium (mMol/L+/−SD	144.1+/−5.5
Initial serum potassium (mMol/L+/−SD)	4.9+/−0.9
Minimal serum potassium (mMol/L+/−SD)	3.7+/−0.7
Peak serum potassium (mMol/L+/−SD)	5.2+/−0.8
Initial NT-proBNP (pg/mL)	10,562+/−10,395
Peak NT-proBNP (pg/mL)	12,298+/−11,505
Initial CRP (mg/L+/−SD)	51.4+/−66.4
Peak CRP (mg/L+/−SD)	134.1+/−105.5
Vasopressors (n and %)	8 (8.4%)
Invasive ventilation (n and %)	12 (12.6%)
Arterial hypertension (n and %)	87 (91.6%)
Diabetes (n and %)	54 (56.8%)
Obesity (n and %)	52 (55.3%)
Preexisting CHF (n and %)	26 (27.4%)
Preexisting CAD (n and %)	39 (41.1%)
COPD (n and %)	18 (18.9%)
Hyperuricemia (n and %)	23 (24.2%)
History of cancer (n and %)	26 (27.4%)
Nephrotoxic drugs (n and %)
NSAIDs	33 (34.7%)
Vancomycin	2 (2.1%)
Aminoglykosides	0
Amphotericin B	0
Other	4 (4.2%)